{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/16559"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/16559","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy","abstract":"INTRODUCTION: Immunotherapy continues to garner strong support for use in the treatment of cancer. Adoptive transfer therapies offer a promising approach to combating metastatic disease. In addition, viruses can also be exploited to drive antitumor immunity and tumor destruction. While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle. METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. We have also evaluated how these therapies interact with pre-conditioning lymphodepletion regimes. RESULTS: In chapter 3, we investigated the differences between three similar chimeric receptors targeting NKG2DL. Upon adoptive transfer, we observed dramatic T cell-induced toxicity. In addition, there were stark differences in the severity of toxicity induced between different receptors or across different mouse strains, or if combined with pre-conditioning chemotherapy. In chapter 4, we tested the ability of oncolytic vaccines to boost engineered T cells through their natural antigen receptor. While CAR-T cells could be boosted via oncolytic vaccines, prolonged T cell engraftment and successful oncolytic vaccine boost required pre-conditioning chemotherapy. Further analysis revealed a lack of antitumor function of the CAR-T cells in vivo. iii In chapter 5, we evaluated loading CAR-T cells with oncolytic viruses (OVs). Loading of CAR-T cells with OV did not impair CAR expression or functionality of the T cells. In addition, CAR target recognition did not impact the ability of OV-loaded cells to deposit OVs onto tumor targets. CAR-T cells loaded with OV also displayed enhanced antitumor functions as compared to either treatment alone. CONCLUSIONS: The research described in this thesis reveals important information into the interactions between CAR-T cells and OVs, and how pre- conditioning regimes may influence responses from either or both therapies. Overall, our research offers novel insight into future CAR-T cell therapeutic developments.","abstract_html":"INTRODUCTION: Immunotherapy continues to garner strong support for use in the treatment of cancer. Adoptive transfer therapies offer a promising approach to combating metastatic disease. In addition, viruses can also be exploited to drive antitumor immunity and tumor destruction. While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle. METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. We have also evaluated how these therapies interact with pre-conditioning lymphodepletion regimes. RESULTS: In chapter 3, we investigated the differences between three similar chimeric receptors targeting NKG2DL. Upon adoptive transfer, we observed dramatic T cell-induced toxicity. In addition, there were stark differences in the severity of toxicity induced between different receptors or across different mouse strains, or if combined with pre-conditioning chemotherapy. In chapter 4, we tested the ability of oncolytic vaccines to boost engineered T cells through their natural antigen receptor. While CAR-T cells could be boosted via oncolytic vaccines, prolonged T cell engraftment and successful oncolytic vaccine boost required pre-conditioning chemotherapy. Further analysis revealed a lack of antitumor function of the CAR-T cells in vivo. iii In chapter 5, we evaluated loading CAR-T cells with oncolytic viruses (OVs). Loading of CAR-T cells with OV did not impair CAR expression or functionality of the T cells. In addition, CAR target recognition did not impact the ability of OV-loaded cells to deposit OVs onto tumor targets. CAR-T cells loaded with OV also displayed enhanced antitumor functions as compared to either treatment alone. CONCLUSIONS: The research described in this thesis reveals important information into the interactions between CAR-T cells and OVs, and how pre- conditioning regimes may influence responses from either or both therapies. Overall, our research offers novel insight into future CAR-T cell therapeutic developments.","abstract_has_math":false,"creators":["VanSeggelen, Heather"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Health Sciences","school":null,"contributors":[],"advisors":["Bramson, Jonathan"],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015-06","date_published":"2015-06","updated_at":"2026-11-18T19:32:15Z","subjects":["immunology","oncology"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/11506"],"render_values":[{"text":"https://doi.org/10.71548/11506","href":"https://doi.org/10.71548/11506","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/16559","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/16559","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F16559","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bramson, Jonathan"]},{"key":"dc:contributor.department","label":"Department","values":["Health Sciences"]},{"key":"dc:creator","label":"Author","values":["VanSeggelen, Heather"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-12-16T15:27:27Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-12-16T15:27:27Z"]},{"key":"dc:date.issued","label":"Date","values":["2015-06"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["immunology","oncology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/16559","https://doi.org/10.71548/11506"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["INTRODUCTION: Immunotherapy continues to garner strong support for use in the treatment of cancer. Adoptive transfer therapies offer a promising approach to combating metastatic disease. In addition, viruses can also be exploited to drive antitumor immunity and tumor destruction. While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle. METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. We have also evaluated how these therapies interact with pre-conditioning lymphodepletion regimes. RESULTS: In chapter 3, we investigated the differences between three similar chimeric receptors targeting NKG2DL. Upon adoptive transfer, we observed dramatic T cell-induced toxicity. In addition, there were stark differences in the severity of toxicity induced between different receptors or across different mouse strains, or if combined with pre-conditioning chemotherapy. In chapter 4, we tested the ability of oncolytic vaccines to boost engineered T cells through their natural antigen receptor. While CAR-T cells could be boosted via oncolytic vaccines, prolonged T cell engraftment and successful oncolytic vaccine boost required pre-conditioning chemotherapy. Further analysis revealed a lack of antitumor function of the CAR-T cells in vivo. iii In chapter 5, we evaluated loading CAR-T cells with oncolytic viruses (OVs). Loading of CAR-T cells with OV did not impair CAR expression or functionality of the T cells. In addition, CAR target recognition did not impact the ability of OV-loaded cells to deposit OVs onto tumor targets. CAR-T cells loaded with OV also displayed enhanced antitumor functions as compared to either treatment alone. CONCLUSIONS: The research described in this thesis reveals important information into the interactions between CAR-T cells and OVs, and how pre- conditioning regimes may influence responses from either or both therapies. Overall, our research offers novel insight into future CAR-T cell therapeutic developments."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bramson, Jonathan"],"dc:contributor.department":["Health Sciences"],"dc:creator":["VanSeggelen, Heather"],"dc:date.accessioned":["2014-12-16T15:27:27Z"],"dc:date.available":["2014-12-16T15:27:27Z"],"dc:date.issued":["2015-06"],"dc:description.abstract":["INTRODUCTION: Immunotherapy continues to garner strong support for use in the treatment of cancer. Adoptive transfer therapies offer a promising approach to combating metastatic disease. In addition, viruses can also be exploited to drive antitumor immunity and tumor destruction. While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle. METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. We have also evaluated how these therapies interact with pre-conditioning lymphodepletion regimes. RESULTS: In chapter 3, we investigated the differences between three similar chimeric receptors targeting NKG2DL. Upon adoptive transfer, we observed dramatic T cell-induced toxicity. In addition, there were stark differences in the severity of toxicity induced between different receptors or across different mouse strains, or if combined with pre-conditioning chemotherapy. In chapter 4, we tested the ability of oncolytic vaccines to boost engineered T cells through their natural antigen receptor. While CAR-T cells could be boosted via oncolytic vaccines, prolonged T cell engraftment and successful oncolytic vaccine boost required pre-conditioning chemotherapy. Further analysis revealed a lack of antitumor function of the CAR-T cells in vivo. iii In chapter 5, we evaluated loading CAR-T cells with oncolytic viruses (OVs). Loading of CAR-T cells with OV did not impair CAR expression or functionality of the T cells. In addition, CAR target recognition did not impact the ability of OV-loaded cells to deposit OVs onto tumor targets. CAR-T cells loaded with OV also displayed enhanced antitumor functions as compared to either treatment alone. CONCLUSIONS: The research described in this thesis reveals important information into the interactions between CAR-T cells and OVs, and how pre- conditioning regimes may influence responses from either or both therapies. Overall, our research offers novel insight into future CAR-T cell therapeutic developments."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["http://hdl.handle.net/11375/16559","https://doi.org/10.71548/11506"],"dc:language.iso":["en"],"dc:subject":["immunology","oncology"],"dc:title":["Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:32:15Z"}